HDBuzz Prize Goes to Study Finding Early EEG Clues in Huntington's

The 2025 HDBuzz Prize has been awarded to research identifying early signs of Huntington's disease in brainwave recordings, before clinical symptoms appear. The winning project, announced by the Huntington's disease research platform HDBuzz, carries the title "Calm Before the Storm: Early Clues of Huntington's Disease Found in Brainwaves."

HDBuzz awards the prize annually to outstanding contributions to Huntington's disease science communication and research. This year's selection directs attention to electrophysiology (the measurement of the brain's electrical activity through techniques such as scalp EEG) as a window into the pre-symptomatic phase of a disease usually tracked by genetics and motor examination.

The framing of the title is instructive. "Calm before the storm" describes the period in which individuals carrying the Huntington's disease mutation show no overt motor symptoms, while "early clues found in brainwaves" points to measurable alterations in neural oscillations during that window.

What does this change for the reading room and monitoring unit?

For clinical neurophysiology readers, the significance is procedural rather than theoretical. If brainwave markers can distinguish mutation carriers from non-carriers before diagnosis, scalp EEG could supplement genetic testing and standardized motor scales in trials of preventive therapy. The award itself does not establish a diagnostic tool; it recognizes research that points electrophysiology toward that frontier.

HDBuzz, which publishes plain-language summaries of Huntington's research, did not detail cohort size, montage specifics, or publication venue in the announcement headline. Readers should treat the prize as a signal of momentum in pre-symptomatic electrophysiology, and await the underlying data for parameters such as sensitivity, specificity, and recording protocol.

The award suggests that in Huntington's disease, as already seen in other neurodegenerative conditions, quantitative EEG may move from research curiosity toward a role in trial enrollment and endpoint measurement. Whether that transition happens depends on replication in larger, prospectively followed cohorts of mutation carriers.